ReviewMolecular biology reports2026
A review of tigecycline resistance in nontuberculous mycobacteria.
Review in Molecular biology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The genus Mycobacterium comprises nontuberculous mycobacteria (NTM), which are opportunistic environmental pathogens primarily associated with chronic lung disease. Among current therapeutic options, tigecycline has emerged as a promising alternative for treating NTM due to its broad spectrum of activity, including efficacy against certain mycobacterial species. In this review, we compiled 28 studies investigating the mechanisms and prevalence of tigecycline resistance in NTM. The evidence suggests that tigecycline is less impacted by the monooxygenase MabTetX, the principal tetracycline resistance determinant in M. abscessus. However, adaptive mechanisms, such as WhiB7 regulation, alterations in the sigH-rshA axis, and overexpression of efflux pumps (MmpL), can increase the minimum inhibitory concentration (MIC). In contrast, slow-growing NTM species, including M. avium and M. kansasii, exhibit low intrinsic susceptibility, reflected by high MIC values. We conclude that tigecycline is a promising component of combination of regimens for rapid-growing NTM, although its efficacy against slow-growing species remains limited and standardized breakpoints have not yet been established. .
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.